Welcome to Pharmaxis

Pharmaxis is a research-based specialist pharmaceutical company with a portfolio of products at various stages of development and approval.  

Company Highlights

Phase 1 clinical trial for SSAO/VAP-1 inhibitor commences

Pharmaxis today announced that it has commenced a Phase 1 clinical trial of  its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A) investigating its potential to treat inflammatory diseases.

Pharmaxis releases interim results for phase I clinical trial of SSAO/VAP-1 inhibitor PXS4728A

Pharmaxis has announced positive interim results from the single ascending dose stage of the Phase 1 clinical trial for its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor PXS4728A.

Significant business milestones: Commercialisation of Bronchitol (Mannitol) in USA, Novaquest dispute settled

Pharmaxis announced it has entered into an exclusive distribution and supply agreement with global pharmaceutical company Chiesi Farmaceutici SpA (Chiesi) for the commercialisation of Bronchitol® (mannitol) in the United States.

Pharmaxis signs agreement with Boehringer Ingelheim for SSA Inhibitor PXS4728A

Pharmaxis has announced it has signed an Option and Asset Purchase Agreement with Boehringer Ingelheim for the SSAO Inhibitor PXS4728A.

 

LATEST NEWS & PUBLICATIONS